Mike Hennessy

A Forum for Ideas, A Forum for Hope

February 21st 2016

It was truly heartening to see Contemporary Radiation Oncology proudly represented by its Editor-in-Chief, Stephen E. Finkelstein, MD, at this year’s Fiesta Bowl.

Enterprising Approaches

February 15th 2016

Separating hype from hope has often been problematic when developments that may lead to advances in the oncology field enter the public domain. The mapping of the human genome and the ability to characterize mutations associated with cancer have spawned one of those waves of excess promises.

Advancing Immunotherapies and Focused Ultrasound Signal a Change

February 5th 2016

The development and approval of high-intensity focused ultrasound doesn’t qualify as moving at a glacial pace; if anything, it seems quite measured. In a crowded field of treatments, the technology is trying to gain a toehold.

Growth Spurt for In-House Pharmacy at Florida Group

February 4th 2016

Despite all you hear about the war between specialty pharma and the independent oncology practice, it is possible for some independents to turn their in-house pharmacy operations into growth machines.

Timing Is Everything

February 2nd 2016

As anticancer therapies continue to improve outcomes for patients, questions about how best to deploy these new options abound. In this issue of OncologyLive, we explore two of the pressing questions that have arisen in treating patients with hematologic malignancies.

Is PD-L1 Just the Tip of the Iceberg?

February 1st 2016

PD-1 and PD-L1 inhibition offers the possibility for precision immuno-oncology through the application of biomarkers that predict the immune systems response. This principle has been demonstrated by two of the most recent FDA approvals for patients with lung cancer.

Game Changers

January 18th 2016

Disruptive technology abounds across a broad range of tumor types and clinicians throughout the spectrum of care will be learning about and adapting to new paradigms.

Palliative Care Makes Good Business Sense

January 18th 2016

More models of care are beginning to show signs of recognition that palliative care has a larger role to play in the oncology setting.

Your Go To Source

December 21st 2015

We’re always talking about the rapid pace of oncology drug development in this era, but perhaps nothing illustrates that trend so clearly as the events of one 15-day period in November.

A New Beginning

December 13th 2015

Immunotherapy's Promise Extends to Bladder and Renal Cell Cancer

December 5th 2015

News stories coming out of the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC) were focused on the emerging role of immunotherapy and radiotherapy in bladder, renal, and prostate cancer.

No Patient Left Behind

December 3rd 2015

The search for biomarkers that can help clinicians match patients with effective therapies continues at a torrid pace in oncology. Yet in the parlance of basketball, not all biomarkers translate into slam dunks when it comes to clinical utility.

LDT Discretion Was Not the Better Part of Valor

December 2nd 2015

The FDA has indicated there are many problems associated with LDTs that clearly warrant a much greater level of oversight to protect the public.

Let's Invest in Research

November 30th 2015

Although there often is controversy over the impact of new cancer drugs on patients’ overall survival, there can be little argument over the broad improvements that have flowed from more than four decades of investment in oncology research.

Work Out the True Value of Services Rendered

November 21st 2015

Site neutrality sounds like something from the Cold War—a zone on a bridge between two ideologically different countries, for instance. In oncology, it’s something completely different.

Series of FDA Approvals Delivers New Hope to Patients

November 14th 2015

With a series of recent approvals, the FDA bolstered oncologists’ armamentarium for treating patients with melanoma, soft tissue sarcoma, and pancreatic cancer.

Far-reaching PSA Guidelines Affect Radiation Oncologists

October 30th 2015

Mixed Study Results in GU Tumor Types Reported From 2015 ECC

October 15th 2015

OncLive Chairman, Mike Hennessy

Fast-Moving Targets

October 12th 2015

There are many reasons, why we must now move beyond the "one drug-one test" model that has resulted in these diagnostics.

Checkpoints at Every Turn

October 12th 2015

Over the last month or so, the immune checkpoint blockade revolution in oncology has officially hit a fever pitch.